Pharmaceutical - Cardio-vascular, Astellas Pharma


Popular Filters

Amgen and Astellas link up on drugs for unmet medical needs in Japan


World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

Japan launches for Lotriga and Argamate


Norway's Pronova BioPharma (OSE: PRON.OL), recently the subject of a $845 million takeover bid from Germany's…

ArgamateAstellas PharmaCardio-vascularLotrigaMarkets & MarketingNephrology and HepatologyNorth AmericaPharmaceuticalPronova BioPharmaSanwa KagakuTakeda Pharmaceuticals

EMA says risk-benefit of ARBs positive; acts on Advagraf and Protelos/Osseor


In a flurry of late news yesterday from the European Medicines Agency and its Committee for Medicinal…

AdvagrafAnti-Arthritics/RheumaticsAstellas PharmaCardio-vascularEuropeImmunologicalsPharmaceuticalProtelosRegulationServier

Astellas drops development of blood thinner darexaban


Japanese drug major Astellas Pharma (TYO: 4503) says it has decided to discontinue the global development…

Astellas PharmaCardio-vasculardarexabanPharmaceuticalRegulationResearch

RUBY-1 trial shows Astellas’ blood thinner darexaban increases bleeding


A Phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban, under development…

Astellas PharmaCardio-vasculardarexabanPharmaceuticalResearch

Back to top